Signs Your Hormone Therapy Dosage Might be Too High

There is a version of the HRT conversation that most women never get to have. They are told it is safe, that it will help, that any bloating or discomfort is the body adjusting. They are told that their blood work is not going to change dramatically and even if it does, it gets put down to ‘ageing”. They are not told that for some women, the dose that helps is not the dose they are given, and that the difference can be like night and day for your body.

I want to have that conversation here. From my own personal experience.

I am going to be direct with you, because you deserve that and it’s the only true and authentic place I can write from. I recently ran my own bloods and found my transferrin saturation at 53%, my urate elevated, my TSH shifted from 2.4 to 3.5, and my triglycerides up from 1.5 to 2.3, not to mention I had gained a huge amount of weight in the last 12 months. My CRP, which had sat reliably at one for years, climbed to three and then settled back to two (still too high for me). All of this in the context of a recent HRT dose that was, for me, too much. Within two weeks of reducing my estrogen dose and modifying my diet, the difference was, in my clinical opinion, remarkable, like a different body. I am sharing this because I think it matters. And because I think the narrative that HRT is universally well-tolerated and that your bloods "won't really change" is a disservice to women who are sitting with symptoms they cannot explain.

The Body Is Always Communicating

When estrogen is introduced or increased, it does not land in a vacuum. It interacts with your liver, your immune system, your lipid metabolism, your stress axis, and your brain. During the menopausal transition, significant rises in triglycerides, LDL cholesterol, and apolipoprotein B have been documented, reflecting the profound metabolic sensitivity of this period. What this tells us is that the menopausal body is not metabolically neutral, and adding exogenous hormones into that environment can tip the balance in ways that are measurable on standard blood panels.

Rises in CRP and elevated triglycerides associated with combined hormone therapy are strongly related to factors including existing metabolic stress and weight changes in postmenopausal women. This is not a reason to avoid HRT. It is a reason to monitor it with the same rigour you would apply to any other medical intervention.

Transdermal oestrogen, applied as a patch, gel, or spray, is considered safer for women at higher risk of blood clots and for those with elevated triglycerides, which is a meaningful distinction that does not always make it into the clinical conversation. The route of delivery is not incidental. It changes how the hormone is metabolised, how it interacts with the liver, and how it registers in your blood work.

The Individual Variation Is Real, and It Is Large

One of the most significant findings in recent research is the degree to which women using the same dose of transdermal oestradiol arrive at completely different serum levels. A 2024 cross-sectional study of perimenopausal and postmenopausal women found that the range in serum oestradiol concentration among transdermal oestradiol users is wide, with considerable interindividual variation even among women using identical doses. One in four women using the highest licensed dose had subtherapeutic oestradiol levels, while others at the same dose would sit substantially higher.

What this means clinically is that a dose appropriate for one woman can be pharmacologically excessive for another. A standard 50 microgram patch is not a standard experience. Research from the British Menopause Society confirms that specific gene polymorphisms of oestrogen receptors can influence dose response, and that it is not currently possible to define a universal threshold from existing evidence. The Goldilocks zone is genuinely individualised, and it requires monitoring to find.

This is not an abstract concern. It shows up in your blood work, in your gut, in your mood, and in your brain.

The FKBP5 gene. When Your Stress Axis Is Already Sensitised

If you carry variants in the FKBP5 gene, your sensitivity to hormonal and physiological change is already heightened. This gene encodes FKBP51, a co-chaperone protein that plays a central role in regulating the hypothalamic-pituitary-adrenal (HPA) axis, which is the body's core stress response system. FKBP51 negatively regulates cortisol effects by inhibiting the interaction between glucocorticoid receptors and cortisol, which reduces the transcription of downstream cortisol molecules. By regulating these cortisol effects, FKBP51 can indirectly regulate the sensitivity of the HPA axis to stressors.

The FKBP5 rs1360780 T allele is associated with an increase in glucocorticoid-induced FKBP5 upregulation, which leads to more dynamic intracellular inhibition of glucocorticoid receptors and can contribute to HPA axis dysregulation and stress-related phenotypes. Studies have documented prolonged cortisol responses and increased anxiety symptoms in T allele carriers after exposure to psychosocial stressors.

What this means for women considering or currently using HRT is significant. Any shift in your hormonal environment, including a dose increase of estrogen, represents a physiological stressor that your HPA axis registers. If FKBP5 variants mean your stress axis is already more reactive, the body's response to a hormonal change that is well-tolerated by the general population can look quite different in you. The bloating, the systemic inflammation markers, the mottled skin, the cognitive symptoms, the mood shifts, these can all be expressions of a stress axis that is responding to a dose that is simply too much for your particular biology and any changes must be done very slowly and strategically to avoid stressing your body out.

Neuroinflammation and the Brain Under Hormonal Stress

The brain is not separate from what is happening in your body. When systemic inflammation rises, the brain feels it. Growing evidence identifies neuroinflammation as a central mediator of psychiatric vulnerability in women, shaped by interactions between sex hormones, immune activation, and neural circuit regulation. Hormonal transitions, including perimenopause, modulate microglial activity, cytokine release, and neuroimmune signalling, creating windows of heightened sensitivity in key brain regions involved in affect regulation, including the amygdala, hippocampus, and prefrontal cortex.

Brain fog, anxiety, low mood, and cognitive slowing during perimenopause are not always symptoms of too little estrogen. They can equally be symptoms of inflammatory burden, of a stress axis under pressure, or of a dose that is pulling the system in a direction it cannot sustain. Research shows that during the menopausal transition, the brain may try to compensate by increasing the density of estrogen receptors, and this adaptation has been associated with poorer memory outcomes in some women, suggesting the brain's regulatory response can at times work against it.

This matters when interpreting cognitive symptoms during HRT. If you are feeling worse mentally on a dose rather than better, that signal is worth investigating rather than waiting out. It doesn’t always feel like a major mood shift, it might feel like a dullness or a grey cloud that doesn’t seem to lift no matter what you do. This could be symptoms of inflammatory load on your brain via cytokines, responding to too much estrogen load.

When You Also Have PCOS

Women who enter perimenopause with a history of polycystic ovary syndrome (PCOS) are navigating an already complex hormonal terrain. PCOS involves years of androgen excess, insulin resistance, and often elevated inflammatory markers. The metabolic backdrop is different, and it warrants a different level of attention when hormone therapy is introduced.

Estrogen plays cardiovascular-protective roles in premenopausal women, but its decline during the menopausal transition leads to increased prevalence of cardiovascular disease, and alterations in lipid profiles are a major contributing factor. For a woman with a PCOS history, where lipid metabolism and insulin sensitivity are already compromised (but not always), the addition of exogenous estrogen at the wrong dose can amplify rather than stabilise these markers.

This does not mean HRT is contraindicated. It means that monitoring is not optional, and that the starting dose should be approached with deliberate caution rather than protocol-first thinking. Often times this can be a very small dose and in my case it should have started under 25mcg. The addition of uterogestan is also something that needs to be timed correctly. With irregular cycles it is much more difficult to find a ‘goldilocks zone’ but not impossible. It does require tracking your cycles and yes even your basel metabolic temperature until you find what works. It is also important to understand how oral and vaginal routes affect you.

What the Blood Work Is Telling You

If your CRP is climbing, your triglycerides are rising, your iron saturation is elevated, or your TSH is shifting since starting or adjusting HRT, these are not incidental findings. They are data. Your body is speaking clearly, and the response should be to listen rather than to wait for the numbers to normalise on their own, they may not and you cannot leave your body in that state.

For me, the interventions that made the most immediate measurable difference were reducing my estrogen dose to closer to 12.5 micrograms, eliminating dairy to reduce dietary inflammatory load, and modifying my iron intake given the elevated transferrin saturation. The changes in how I felt within two weeks were significant enough that I want to say, sometimes less is more, and your body will show you the difference but you must not be afraid to trust it.

How to Know If Your Dose Is Right

There is no universal answer here, but there are questions worth asking, and they deserve honest clinical consideration:

Your symptoms are the first signal. Persistent bloating, worsening mood or cognition, increasing fatigue, digestive disruption, or the sense that something is generally not right since your dose was adjusted, for example, a huge gain in weight or lipoedema or swollen legs - these are reasons to investigate, not to override.

Your blood work is the second signal. CRP, triglycerides, liver markers, thyroid function, and iron studies can all shift in response to oestrogen, particularly at higher doses or in women with pre-existing metabolic sensitivities. Requesting a full panel and comparing it to your baseline is not overcautious. It is appropriate clinical care.

Your subjective experience is valid data. The assumption that symptoms will settle is not always correct, and a woman who reports that she felt better at a lower dose deserves to be taken seriously rather than reassured out of her own experience.

The Adjustment You Did Not Expect

One thing worth naming, particularly for women who reduce their dose, lowering estrogen has its own consequences. The tissues, ligaments, and structures that were running on higher estrogen will feel the change. Joint laxity, skin changes, changes in vaginal tissue, shifts in mood (not always though) these are not signs that the lower dose is wrong. They are signs that your body is adjusting to a new hormonal environment, and that adjustment takes time and nutritional support.

Prioritising anti-inflammatory nutrition, adequate protein, and dietary fat from quality sources during any dose adjustment period can help to buffer the transition. This is not a peripheral consideration. It is core to managing the physiological response.

A Different Standard of Care

Women deserve to have these conversations with their prescribing clinicians. They deserve to know that interindividual variation in oestrogen response is not a fringe concern but a documented clinical reality. They deserve to know that their bloods can and do change, and that those changes carry information worth acting on.

More is not always better. The right dose is the one that works for your biology, at your stage of transition, with your genetics and with your existing metabolic picture. Finding it takes time and often more time that you might think or want, careful monitoring, and a willingness to adjust when the evidence suggests it. I know its a tough ride but your health is worth it darling.

Strong, fuelled, and metabolically well. That is the standard worth working toward.

References

Glynne, S., Reisel, D., Kamal, A., Neville, A., McColl, L., Lewis, R. and Newson, L. (2024) 'The range and variation in serum estradiol concentration in perimenopausal and postmenopausal women treated with transdermal estradiol in a real-world setting: a cross-sectional study', Menopause, 32(2), pp. 103–111. doi: 10.1097/GME.0000000000002459.

Konieczna, J., Abete, I., Galmés, A.M., Babio, N., Coloma, A., Toledo, E., Corella, D., Fitó, M., Muñoz-Garach, A., Martínez, J.A., et al. (2022) 'Body adiposity indicators and cardiometabolic risk: cross-sectional analysis in participants with overweight or obesity from the PREDIMED-Plus trial', Nutrition, Metabolism and Cardiovascular Diseases, 32(6), pp. 1460–1470.

Mosconi, L., Carnez, B., Diaz, I., Rahman, A., Hristov, H., Andrews, R., Osorio, R.S., Isaacson, R.S., Brinton, R.D. and Dyke, J.P. (2024) 'Estrogen-mediated neuroprotection of the female brain: current evidence and clinical implications', Neuron, 112(5), pp. 740–759.

Nappi, R.E., Chedraui, P., Lambrinoudaki, I. and Simoncini, T. (2022) 'Menopause: a cardiometabolic transition', The Lancet Diabetes and Endocrinology, 10(6), pp. 442–456. doi: 10.1016/S2213-8587(22)00076-6.

Prokai-Tatrai, K., De La Cruz, D.L., Nguyen, V., Sahyouni, M., Khan, M.N., Prokai, L. and Singh, M. (2024) 'Estrogen-derived neurosteroids and neuroinflammation: a preclinical update', Frontiers in Neuroendocrinology, 73, 101129.

Schiele, M.A., Gottschalk, M.G. and Domschke, K. (2020) 'The applied implications of epigenetics in anxiety, affective and stress-related disorders: a review and synthesis on psychosocial stress, education and intervention', Clinical Psychology Review, 77, 101830.

Slopen, N., Kubzansky, L.D., McLaughlin, K.A. and Koenen, K.C. (2019) 'Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-κB-driven inflammation and cardiovascular risk', Proceedings of the National Academy of Sciences, 116(23), pp. 11370–11379. doi: 10.1073/pnas.1816847116.

Stanczyk, F.Z. and Clarke, N.J. (2023) 'Measurement of serum estradiol in the menopause transition: challenges and clinical implications', British Menopause Society Tools for Clinicians, British Menopause Society.

Toffoletto, S., Lanzenberger, R., Gingnell, M., Sundström-Poromaa, I. and Comasco, E. (2023) 'Neuroinflammation and the female brain: sex-specific mechanisms underlying mood disorders and stress vulnerability', PMC Neuroscience Review, published online March 2025.

Yoshida, T., Yam, G.H.F., Mehrotra, A. and Wang, M. (2023) 'Neuroinflammation and sex-specific mechanisms in mood disorders and stress vulnerability', Frontiers in Reproductive Health, review synthesis.

About the Author: Combining professional expertise with personal insight, I am a nutritional scientist dedicated to changing the conversation around women's hormonal health. Having navigated the hidden complexities of HRT over-treatment myself, I bridge the gap between clinical research and real-world experience to ensure women have the tools they need to advocate for their health. If you're a woman in perimenopause struggling with metabolic health despite doing "all the right things," the missing piece might be understanding your unique internal landscape. My Sérenité Women's Wellness Program uses blood pathology analysis to create truly personalized nutrition protocols that work with your specific metabolism. Learn more about working together